Welcome to LookChem.com Sign In|Join Free

CAS

  • or

128253-31-6

Post Buying Request

128253-31-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

128253-31-6 Usage

Uses

Prevention of acute cardiovascular events.

Biological Activity

bay-x 1005 is a selective inhibitor of 5-lipoxygenase-activating protein [1].5-lipoxygenase-activating protein (flap) is an integral protein and plays an important role in the activation of 5-lipoxygenase (5-lox) and the synthesis of leukotrienes, which regulating immune responses.bay-x 1005 is a selective inhibitor of leukotriene synthesis. bay x 1005 binds to flap and inhibits 5-lox translocation from the cytosol to membranes [1]. bay-x1005 inhibited ltb4 synthesis with ic50 values of 0.22, 0.026 and 0.039 μm for isolated pmnl of human, rat and mouse respectively and inhibited ltc4 synthesis with ic50 value of 0.021 μm in mouse macrophages [2].in the arachidonate-induced mouse ear inflammation test, bay-x 1005 inhibited myeloperoxidase activity and edema formation with ed50 values of 7.9 and 48.7, respectively [2].also, bay-x 1005 (100 mg/kg) reduced platelet-activating factor-induced death of mice by 51% in a dose-dependent way. in animal models, bay-x 1005 inhibited the synthesis of ltb4 and ltc4, which reduced edema formation, the vascular phenomena of inflammation and leukocyte immigration [3].

references

[1]. hatzelmann a, fruchtmann r, mohrs kh, et al. mode of action of the leukotriene synthesis (flap) inhibitor bay x 1005: implications for biological regulation of 5-lipoxygenase. agents actions, 1994, 43(1-2): 64-68.[2]. müller-peddinghaus r, fruchtmann r, ahr hj, et al. bay x1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. j lipid mediat, 1993, 6(1-3): 245-248.[3]. müller-peddinghaus r, kohlsdorfer c, theisen-popp p, et al. bay x1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. j pharmacol exp ther, 1993, 267(1): 51-57.

Check Digit Verification of cas no

The CAS Registry Mumber 128253-31-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,2,5 and 3 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 128253-31:
(8*1)+(7*2)+(6*8)+(5*2)+(4*5)+(3*3)+(2*3)+(1*1)=116
116 % 10 = 6
So 128253-31-6 is a valid CAS Registry Number.
InChI:InChI=1/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)

128253-31-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML0411)  BAY-X-1005  ≥98% (HPLC)

  • 128253-31-6

  • SML0411-5MG

  • 1,301.04CNY

  • Detail
  • Sigma

  • (SML0411)  BAY-X-1005  ≥98% (HPLC)

  • 128253-31-6

  • SML0411-25MG

  • 5,253.30CNY

  • Detail

128253-31-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid

1.2 Other means of identification

Product number -
Other names DG-031

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:128253-31-6 SDS

128253-31-6Relevant articles and documents

Ru-catalyzed asymmetric hydrogenation of racemic aldehydes via dynamic kinetic resolution: Efficient synthesis of optically active primary alcohols

Xie, Jian-Hua,Zhou, Zhang-Tao,Kong, Wei-Ling,Zhou, Qi-Lin

, p. 1868 - 1869 (2007/10/03)

A highly efficient asymmetric hydrogenation of racemic α-arylaldehydes via dynamic kinetic resolution has been developed by using [RuCl2(SDPs)(diamine)] complexes as catalysts, providing chiral primary alcohols in excellent enantioselectivities. Copyright

Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors

-

, (2008/06/13)

Described are methods for ameliorating symptoms associated with inflammatory bowel disease such as ulcerative colitis and Crohn's disease (regional enteritis) with four specific quinoline leukotriene synthesis inhibitors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 128253-31-6